Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shannon M. Pfeiffer
Observed name:
Shannon Pfeiffer
Institutions:
University of California, Irvine,
Parker Institute for Cancer Immunotherapy
Observed institutions:
Genentech,
University of California, Irvine,
Parker Institute for Cancer Immunotherapy
ORCID:
0000-0002-4291-9483
Observed ORCID:
0000-0002-4291-9483
OpenAlex ID:
A5084327129
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022
·
Lacey J. Padrón
, Deena M. Maurer
, et al.
·
Nature Medicine
·
411
PDF
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
2024
·
Bridget M. Fortin
, Shannon M. Pfeiffer
, et al.
·
Nature Immunology
·
157
PDF
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
2023
·
Katie M. Campbell
, Meelad Amouzgar
, et al.
·
Cancer Cell
·
92
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
2024
·
Jacob E. Till
, Lee McDaniel
, et al.
·
Nature Communications
·
19
PDF
Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐ PD ‐1/ PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
2022
·
Cristina Julian
, Robson J. M. Machado
, et al.
·
Cancer Reports
·
16
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
2024
·
Apostolia M. Tsimberidou
, Farah A. Alayli
, et al.
·
The Journal of Experimental Medicine
·
13
PDF
587 AMADEUS trial: tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration
2022
·
Farah Alayli
, Kwame Okrah
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Primary tumor type prediction based on US nationwide genomic profiling data in 13,522 patients
2023
·
Yunru Huang
, Shannon M. Pfeiffer
, et al.
·
Computational and Structural Biotechnology Journal
·
1
PDF
Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy.
2022
·
Jacob Edward Till
, Lee McDaniel
, et al.
·
Journal of Clinical Oncology
·
1
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
2021
·
Deena Maurer
, Jia Xin Yu
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 3818: Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma
2022
·
Katie M. Campbell
, Justin Saco
, et al.
·
Cancer Research
Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
2022
·
Lacey J. Padrón
, Deena M. Maurer
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
12
Citation count:
713
H-index:
6
I10-index:
6
Year
Topic
Type